# EDGAR Filing Document

**Accession Number:** 0001821956
**File Stem:** 0001104659-25-073798
**Filing Date:** 2025-8
**Character Count:** 7917
**Document Hash:** 2636090fc6e255a9d2b07082e0e4b3c4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-073798.hdr.sgml**: 20250804

**ACCESSION NUMBER**: 0001104659-25-073798

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250731

**FILED AS OF DATE**: 20250804

**DATE AS OF CHANGE**: 20250804

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Hussain Abbas
- **CENTRAL INDEX KEY:** 0001821956

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35803
- **FILM NUMBER:** 251182463

**MAIL ADDRESS:**
- **STREET 1:** C/O TEVA
- **STREET 2:** 5 BASEL STREET, P.O. BOX 3190
- **CITY:** PETACH TIKVA
- **STATE:** L3
- **ZIP:** 4951033
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mallinckrodt plc
- **CENTRAL INDEX KEY:** 0001567892
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981088325
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1226

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15
- **BUSINESS PHONE:** 353 1 6960000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Hussain Abbas<br><sub>(Last) (First) (Middle)</sub><br>675 MCDONNELL BLVD.<br><sub>(Street)</sub><br>HAZELWOOD, MO 63042<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Mallinckrodt plc [ NONE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2025-07-31 |  | M |  | 12036 | A | <sup>(1)</sup> | 13216 | D |  |
| Ordinary Shares | 2025-07-31 |  | F |  | 3433 | D | <sup>(2)</sup> | 9783 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(3)</sup> | 2025-07-31 |  | A |  | 16414 |  | <sup>(3)</sup> | <sup>(3)</sup> | Ordinary Shares | 16414 | $0.00 | 21886 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | 2025-07-31 |  | D |  |  | 9850 | <sup>(4)</sup> | <sup>(4)</sup> | Ordinary Shares | 9850 | <sup>(5)</sup> | 12036 | D |  |
| Restricted Stock Units | <sup>(1)</sup> | 2025-07-31 |  | M |  |  | 12036 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 12036 | $0.00 | 0 | D |  |

---

### Footnotes:

(1) On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU.

(2) The number of ordinary shares withheld to satisfy tax withholding obligations arising out of the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.

(3) Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into an RSU.

(4) The reporting person entered into an agreement with the Issuer pursuant to which the reporting person forfeited the right to receive 9,850 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest.

(5) The number of RSUs forfeited is based on a percentage.

**Remarks:**
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.

**Signature:** /s/ Mark Tyndall, Attorney-in-Fact  
**Date:** 2025-08-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**